Opinion
Video
Clinical Attributes of Patients Who Would Benefit From Micronized Abiraterone
Author(s):
Panelists discuss how criteria such as patient comorbidities, disease progression levels, and treatment goals should be considered when selecting the appropriate form of abiraterone for patients with mCRPC, and also explore the potential benefits and drawbacks of using micronized abiraterone in specific patient populations.
- In your opinion, what criteria should be considered when selecting the appropriate form of abiraterone for patients with mCRPC?
- What are the potential benefits or drawbacks when using micronized abiraterone in specific patient populations (eg, those with comorbidities or differing levels of disease progression)?
Related Content
